160 related articles for article (PubMed ID: 15012688)
1. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
[TBL] [Abstract][Full Text] [Related]
2. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
3. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
6. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
7. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
van Esch S; Zweers MM; Jansen MA; de Waart DR; van Manen JG; Krediet RT
Perit Dial Int; 2004; 24(6):554-61. PubMed ID: 15559485
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
[TBL] [Abstract][Full Text] [Related]
9. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
Do JY; Kim YL; Park JW; Cho KH; Kim TW; Yoon KW; Kim CD; Park SH; Han JH; Song IH
Perit Dial Int; 2005 Feb; 25 Suppl 3():S22-5. PubMed ID: 16048250
[TBL] [Abstract][Full Text] [Related]
10. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
11. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
13. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
14. Dialysate CA125 levels in children on continuous peritoneal dialysis.
Turhan P; Sever L; Caliskan S; Kasapcopur O; Sever A; Hacibekiroglu M; Arisoy N
Pediatr Nephrol; 2005 Nov; 20(11):1615-21. PubMed ID: 16133054
[TBL] [Abstract][Full Text] [Related]
15. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag.
Cappelli G; Bandiani G; Cancarini GC; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
Adv Perit Dial; 1999; 15():238-42. PubMed ID: 10682110
[TBL] [Abstract][Full Text] [Related]
16. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.
Pannekeet MM; Zemel D; Koomen GC; Struijk DG; Krediet RT
Perit Dial Int; 1995; 15(6):217-25. PubMed ID: 7578497
[TBL] [Abstract][Full Text] [Related]
17. Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products.
Wieczorowska-Tobis K; Brelinska R; Witowski J; Passlick-Deetjen J; Schaub TP; Schilling H; Breborowicz A
Perit Dial Int; 2004; 24(1):48-57. PubMed ID: 15104336
[TBL] [Abstract][Full Text] [Related]
18. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.
Jones S; Holmes CJ; Krediet RT; Mackenzie R; Faict D; Tranaeus A; Williams JD; Coles GA; Topley N;
Kidney Int; 2001 Apr; 59(4):1529-38. PubMed ID: 11260417
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]